MR-proADM Diabetes Diagnosis Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing diabetes mellitus, particularly type II, face challenges due to the instability of adrenomedullin, making reliable plasma-based diagnoses unreliable, and existing methods do not effectively utilize midregional proAdrenomedullin (MR-proADM) for diabetes diagnosis.
Innovation Solution
A method for in-vitro diagnosis and risk stratification of diabetes mellitus using midregional proAdrenomedullin (MR-proADM) or its partial peptides, combined with other markers, to determine the severity and complications of diabetes, employing techniques like immunoassays and lateral-flow tests for rapid and accurate assessments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adrenomedullin is used as a diagnostic marker for diabetes mellitus, then the diagnosis can be made based on the known relationship with diabetic microangiopathy, but the short duration and instability of adrenomedullin in plasma make reliable diagnosis impossible
Solution Approach 1:
The patent segments the adrenomedullin protein into different parts: the unstable N-terminal region and the stable C-terminal region (MR-proADM). By measuring only the stable C-terminal fragment, the patent achieves reliable diagnosis while avoiding the instability problem of the full adrenomedullin molecule.
Solution Approach 2:
The patent extracts and measures only the stable midregional proAdrenomedullin (MR-proADM) fragment from the complete adrenomedullin structure. This extraction of the stable fragment allows for reliable plasma-based diagnosis without being affected by the short half-life of the complete adrenomedullin molecule.
2Reliability
If existing proAdrenomedullin determination methods are used, then sepsis diagnosis is improved, but the suitability for diabetes mellitus diagnosis is not established and requires further validation
Solution Approach 1:
The patent applies the universal diagnostic approach by using MR-proADM for multiple indications including both sepsis and diabetes mellitus. The same stable fragment and measurement methodology serve different diagnostic purposes, reducing the need for separate validation systems while establishing reliability across different disease contexts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables reliable and rapid diagnosis and risk stratification of diabetes mellitus, particularly type II, allowing for more effective clinical decisions and treatment strategies by leveraging the high plasma stability of MR-proADM and its correlation with diabetes severity and complications.
Implementation Method 1
employing techniques like immunoassays and lateral-flow tests for rapid and accurate assessments
Implementation Method 2
employing techniques like immunoassays and lateral-flow tests for rapid and accurate assessments
Implementation Method 3
employing techniques like immunoassays and lateral-flow tests for rapid and accurate assessments
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No. 2) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method.